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Abstract
Background: Asthma is a chronic airway inflammatory disease characterized by an imbalance in
both Th1 and Th2 cytokines. Exhaled nitric oxide (NO) is elevated in asthma, and is a potentially
useful non-invasive marker of airway inflammation. However, the origin and underlying mechanisms
of intersubject variability of exhaled NO are not yet fully understood. We have previously
described NO gas phase release from normal human bronchial epithelial cells (NHBEs, tracheal
origin). However, smaller airways are the major site of morbidity in asthma. We hypothesized that
IL-13 or cytomix (IL-1β, TNF-α, and IFN-γ) stimulation of differentiated small airway epithelial cells
(SAECs, generation 10–12) and A549 cells (model cell line of alveolar type II cells) in culture would
enhance NO gas phase release.
Methods: Confluent monolayers of SAECs and A549 cells were cultured in Transwell plates and
SAECs were allowed to differentiate into ciliated and mucus producing cells at an air-liquid
interface. The cells were then stimulated with IL-13 (10 ng/mL) or cytomix (10 ng/mL for each
cytokine). Gas phase NO release in the headspace air over the cells was measured for 48 hours
using a chemiluminescence analyzer.
Results: In contrast to our previous result in NHBE, baseline NO release from SAECs and A549
is negligible. However, NO release is significantly increased by cytomix (0.51 ± 0.18 and 0.29 ± 0.20
pl.s-1.cm-2, respectively) reaching a peak at approximately 10 hours. iNOS protein expression
increases in a consistent pattern both temporally and in magnitude. In contrast, IL-13 only modestly
increases NO release in SAECs reaching a peak (0.06 ± 0.03 pl.s-1.cm-2) more slowly (30 to 48
hours), and does not alter NO release in A549 cells.
Conclusion: We conclude that the airway epithelium is a probable source of NO in the exhaled
breath, and intersubject variability may be due, in part, to variability in the type (Th1 vs Th2) and
location (large vs small airway) of inflammation.
Background
Asthma is a chronic inflammatory disease characterized
by airway hyperresponsiveness and variable airflow
obstruction. Activation of eosinophils, T lymphocytes,
neutrophils and macrophages are all involved in airway
inflammation, which can trigger the release of mediators
and cytokines that contribute to the clinical syndrome of
asthma. Among these, IL-13, a cytokine derived from type
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2 lymphocytes (Th2), has been proposed to play a major
role in the development of atopic asthma [1]. In addition,
cytokines secreted by type 1 lymphocytes (Th1) and mac-
rophages, including IL-1β, TNF-α, and IFN-γ, may be
increased in asthma subjects and contribute to the inflam-
matory process [2].
Inflammation in asthma occurs throughout the airway
tree. Increasing evidence demonstrates that inflammation
of smaller airways (diameter < 2 mm) is significant, and
contributes to airways hyperresponsiveness, nocturnal
asthma, and asthma exacerbations [3]. Because of the rel-
ative inaccessibility of small airways, examination of the
inflammatory process is mainly limited to post-mortem
or bronchial biopsy analysis while dynamic in vivo assess-
ment remains limited to estimates of small airway and
alveolar concentration based on exhaled NO levels and
mathematical models [4].
The fractional concentration of exhaled nitric oxide
(FENO) is a potential biomarker of inflammation in
asthma, which may be useful in both diagnosis and treat-
ment. FENO increases in untreated asthma, and decreases
with corticosteroid treatment [5], but its clinical utility
remains limited mainly due to significant intersubject var-
iability. The exhaled NO signal can be partitioned into air-
way and alveolar components by measuring exhaled NO
at multiple flows and applying mathematical models.
Studies suggest that alveolar NO is a measure of inflam-
mation in the distal lung [6]. Increased iNOS (inducible
nitric oxide synthase, NOSII) expression in airway epithe-
lial cells has been proposed to be the main source of
exhaled NO [7]. Our recent study directly measured gas
phase NO release in primary normal human bronchial
epithelial cells (NHBEs) of tracheal origin, and demon-
strated significant intersubject variability in response to
IL-13 [8]. NO production has not been directly examined
in airway epithelial cells of small airway origin.
We hypothesized that primary human small airway epi-
thelial cells (SAECs) would produce detectable NO gas
phase release following stimulation by IL-13 and cytomix
(IL-1β, TNF-α, and IFN-γ). A549 cells (human lung epi-
thelial carcinoma cell line, model of human alveolar epi-
thelial type II cells), which have been used extensively for
the investigation of NO metabolism [9-13], were also uti-
lized in this study. Our results demonstrate that cytomix
rapidly (<10 hours) upregulates iNOS expression and gas
phase NO release in both SAECs and A549. In contrast, IL-
13 did not induce significant NO release in A549 cells,
and caused only a modest, and delayed (30 to 48 hours),
response from SAECs. This suggests the small airway epi-
thelium is a likely source of exhaled NO in inflammatory
diseases such as asthma, and responds to inflammatory
stimuli in a pattern distinct from epithelial cells of large
airway origin [8].
Materials and methods
Cell culture
Cryopreserved passage 1 small airway epithelial cells
(SAECs) from 3 different donors (donor1: 4F0715, donor
2: 6F3342, donor 3: 6F3426) were purchased from Lonza
(formerly Cambrex, Walkersville, MD) and grown on T-
75 cm2 flasks (Corning, Fisher) in a 37°C, 5% CO2/95%
air incubator in small airway epithelial basal medium
(SABM) supplemented with growth factors supplied in
the SAGM SingleQuot® kit (Lonza). At passage 3, cells
were trypsinized and seeded onto Costar Transwells®
inserts with 0.4 μm pore size (Corning, Fisher) at a density
of 2.0 × 105cells/well in media comprised of 50% SABM
and 50% DMEM-F12 low glucose (Invitrogen, Carlsbad,
CA) with the same final concentration of supplements as
used for flasks, and additional retinoic acid (50 nM).
Medium was applied both apically and basally until the
cells reached confluence, at which time an air-liquid inter-
face (ALI) was established for 7 days to achieve mucocili-
ary differentiation. The media was changed every other
day, and transepithelial electrical resistance (TER) was
measured by Millicell-ERS (Millipore, Bedford, MA) at
room temperature every other day starting from the sec-
ond day of ALI.
A549 cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD) and were grown on T-
75 cm2 flasks (Corning, Fisher) in a 37°C, 5% CO2/95%
air incubator in F12-k medium (ATCC, Rockville, MD)
containing 10% fetal bovine serum (Mediatech, VA), pen-
icillin (100 U/ml, Mediatech, VA) and streptomycin (100
μg/ml, Mediatech, VA). When subconfluent, cells were
trypsinized and seeded onto Costar Transwells® inserts
with 0.4 μm pore size (Corning, Fisher) at a density of 2.0
× 105 cells/well. Once the cells reached confluence, they
were shifted to ALI culture for 2 days.
Immunofluoresent staining for cell differentiation markers
After 7 days of ALI, SAECs were fixed in 4% paraformalde-
hyde for 30 mins and then permeabilized with 1% Triton
X-100 in PBS for 20 min. Nonspecific immunogloblin
binding was blocked by incubation with 5% normal goat
serum in PBS for 1 h at room temperature. Mouse mono-
clonal antibodies against ZO-1 (1:250 dilution; Zymed
Laboratories, South San Francisco, CA), β-tubulin IV
(1:1000 dilution; Sigma, St. Louis, MO), and mucin 5AC
(MUC5AC, 1:1000 dilution; Neo Markers, Fremont, CA)
were diluted in PBS with 5% goat serum and incubated at
4°C overnight. The samples were washed and then incu-
bated in Alexa Fluor 488 anti-mouse secondary antibody
(Molecular Probes, Eugene, OR) diluted 1:500 in PBS
with 5% goat serum for 2 hours at 4°C. Cell nuclei wereRespiratory Research 2009, 10:3 http://respiratory-research.com/content/10/1/3
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stained with 4', 6-diamidino-2-phenylindole dihydro-
cholride hydrate (1 μg/ml, DAPI, Sigma) in PBS for 5 min-
utes. Fluorescence images were obtained using a Nikon
Eclipse E800 epifluorescence microscope.
Stimulation of SAECs and A549 with cytomix or IL-13
Culture medium was changed 24 hours prior to the exper-
iment. On the day of the experiment (t = 0 hour), cytomix
(TNF-α, IL-1β, IFN-γ, R&D Systems, Minneapolis, MN)
was added to fresh culture medium to achieve a final con-
centration of 10 ng/ml each. For the IL-13 group, IL-13
(R&D Systems, Minneapolis, MN) was added to the
medium to achieve a final concentration of 10 ng/ml.
Concentrations of cytokines were based on previous
reports to achieve iNOS expression without compromis-
ing cell viability [8,10,14]. 24 hours after the experiment
started, 30 μM iNOS inhibitor L-NIL (N6-(1-iminoethyl)-
L-lysinem, Cayman chemical, Ann Arbor, MI) was added
to the cytomix treated culture medium in some experi-
ments. The total duration of each experiment was 48
hours.
Gas phase NO measurement and NO flux calculation
12-well Transwell® plates were fitted with modified lids
and edges were sealed with Parafilm M (Menasha, WI) to
form a gas tight enclosure. Holes were drilled on the top
surface of the lids. The plates were placed in a 37°C, 5%
CO2/95% air incubator and one of the holes was con-
nected to the inlet of a chemiluminescent nitric oxide ana-
lyzer (NOA 280, Sievers, Boulder, CO) via a flow meter. A
constant flow (Q) of 40 ml/s was used to ensure an accu-
rate reading from the NOA. The rate of NO gas transport
(flux) from the cells to the airstream is independent of the
gas flow due to the low water solubility of NO [4]. Real
time NO data at different time points from the NOA was
collected for further analysis. NO flux was calculated as
previously described [8]. Multiple measurements were
performed between 7 to 21 days following air-liquid
interface. In brief, real time NO reaches a plateau value,
Cp (ppb), representing the steady state NO release into
the gas phase after the washout of accumulated NO from
the headspace. Steady state NO concentrations were deter-
mined by fitting an exponential form to the smoothed
transient response and the NO flux was calculated as F =
QCp/As (pl.s-1.cm-2) based on the surface area, As, of the
Transwells.
Total nitrite+nitrate assay
Total nitrite+nitrate in the culture medium was measured
by a Griess assay kit (Cayman Chemical, Ann Arbor, MI)
according to the manufacturer's instructions. Nitrate in
the sample medium and standards were converted to
nitrite by nitrate reductase, and Griess reagent was added
in the 96 well plate. Absorbance was determined at 540
nm. The concentration of total nitrite+nitrate was calcu-
lated according to a standard curve of known nitrite con-
centrations.
Western Blotting
At each time point after NO gas phase measurement, pro-
tein was extracted using RIPA buffer and quantified using
the Bradford assay (BioRad). Samples (40 μg equal pro-
tein) were subjected to 7.5% SDS-PAGE and transferred to
a Polyvinylidene fluoride (PVDF) membrane (Millipore,
Bedford, MA). The blots were probed with monoclonal
mouse anti-iNOS antibody (Research and Development
Antibodies, Las Vega, NV) using 1:1000 dilution in TBST
with 2% goat serum and subsequently incubated with
horseradish peroxidase (HRP) conjugated secondary anti-
bodies (1:10,000, Santa Cruz biotechnology, Santa Cruz,
CA). The proteins were visualized using an enhanced
chemiluminescence system (Amersham Biosciences and
Biorad Imaging system). The blots were also probed with
mouse monoclonal anti-β-actin (Abcam, Cambridge,
MA) as a loading control.
Reverse Transcription and PCR
At the end of experiment (t = 48 hours), RNA was col-
lected from control, cytomix treated and IL-13 treated
groups. Total RNA was isolated using NucleoSpin® RNA II
kit (Macherey-Nagel, PA) and quantified by Quant-iT™
RiboGreen®  RNA assay kit (Invitrogen, Carlsbad, CA).
Reverse transcription was carried out using TaqMan® rea-
gents (Applied Biosystems, Foster City, CA). Gene expres-
sion of the NOS isoforms was probed via PCR using the
primers 5'-GCCTCGCTCTGGAAAGA-3', 3'-TTCCAACA-
GACGTACCT-5' (iNOS); 5'-AGGACAGACGGCAAG-
CACGA-3', 3'-GGTGGCGGAGTGATGGTCAA-5' (nNOS);
5'-CAGTGTCCAACATGCTGCTGGAAATTG-3', 3'-CCG-
TAGTGGTCCTTCTTCTGGAAAT-5' (eNOS). Ribosomal
18S RNA (Applied Biosystems, Foster City, CA) was used
as an internal standard.
Statistics
Experiments were performed using three different SAEC
donors with multiple repeats of each donor. Data are pre-
sented as Mean ± SD and statistical significance was tested
using a two-tailed Student's t-test; p values less than 0.05
were considered significant.
Results
Small airway epithelial cells differentiation
Immunofluorescent staining for MUC5AC, β – Tubulin IV
and ZO-1 was detected after 7 days of ALI. A small number
of SAECs expressed MUC5AC (Fig. 1A), a marker for
mucous differentiation and β – Tubulin IV (Fig. 1B), a
marker for ciliary differentiation. ZO-1 (Fig. 1C) staining
showed a highly organized, mature cell-cell junction. TER
climbed to 700 ohms-cm2 after 7 days of ALI and gradu-
ally reached a peak of approximately 1500 ohms-cm2 fol-Respiratory Research 2009, 10:3 http://respiratory-research.com/content/10/1/3
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lowing approximately 18 days of ALI (Fig. 1D). TER data
represent the mean response from 2 different donors.
These phenotypic markers were stable in culture for more
than 2 weeks.
Cytomix and IL-13 induces NO releases into gas phase and 
total nitrate formation in SAECs and A549
NO gas phase concentration in control, cytomix-treated or
IL-13-treated cells was measured at different time points
up to 48 hours and the NO flux was calculated. Basal level
of NO gas phase release was negligible in both types of
cells. Cytomix induced significant NO release at 6 hours
and the peak NO flux was observed on average at 10 hours
after stimulation (0.51 ± 0.18 and 0.29 ± 0.20 pl.s-1.cm2
for SAECs and A549 cells respectively) (Fig. 2B, D). Addi-
tion of iNOS inhibitor at 24 hours rapidly and signifi-
cantly reduced the NO flux (Fig. 2B). In contrast, IL-13
Phenotypic markers of human small airway epithelial cells  (SAECs) cultured at an air-liquid interface Figure 1
Phenotypic markers of human small airway epithelial 
cells (SAECs) cultured at an air-liquid interface. Day 0 
represents the first day of air-liquid interface which is gener-
ally 48 hours after seeding on the membrane, and all repre-
sentative images were taken at day 7. A: 
Immunofluorescence imaging of MUC5AC (green) demon-
strating the presence of mucous granules. B: Immunofluores-
cence imaging of β-tubulin IV (green) demonstrates the 
presence of ciliated cells. C: Immunofluorescence imaging of 
zonula occludens-1 (ZO-1) (green), a key protein present in 
the intercellular tight junctions. Cell nuclei were counter-
stained blue by DAPI. D: Transepithelial electrical resistance 
(TER) was measured every other day from 2 days of ALI. 
TER data represent the mean response from 2 different 
donors (12 monolayers from each donor). Scale bar: 10 μm.
Gas phase NO release from stimulated SAECs/A549 cells  and total nitrate/nitrite in culture medium Figure 2
Gas phase NO release from stimulated SAECs/A549 
cells and total nitrate/nitrite in culture medium. Data 
is the mean values from 3 donors. A: Representative real-
time NO signal from the NO analyzer. Raw analyzer data 
was smoothed using a wavelet transformation, and the steady 
state value determined from an exponential fit as previously 
described [8]. B: Cytomix or IL-13 was added to the SAEC 
culture medium at t = 0. Gas phase NO concentration and 
was measured at different times (0, 6, 10, 24, 30, 34 hours) 
up to 48 hours, and the NO steady state flux was calculated 
as described in the Methods. Very low level of basal NO flux 
was detected from SAECs (n = 6, data from 6 measure-
ments). NO flux was increased by cytomix treatment within 
6 hours and reached a peak at 10 hours (n = 10 or 11). At t = 
24 hours, 30 μM iNOS inhibitor L-NIL was added to the cul-
ture medium in some experiments leading to a significant 
reduction of NO flux (n = 4). IL-13 induced modest increase 
in NO flux in SAECs (n = 8 or 9, *P < 0.05 compared to con-
trol group, #P < 0.05 compared to cytomix stimulated 
group). C: Total nitrite+nitrate content in SAECs culture 
medium after 48 hours exposure to either cytomix or IL-13 
was measured (n = 10, *P < 0.05 compared to control 
group). D: Cytomix or IL-13 was added to A549 cell culture 
medium at t = 0. NO flux was increased by cytomix treat-
ment within 6 hours and reached a peak at 10 hours. IL-13 
did not alter the NO flux (n = 4, *P < 0.05 compared to con-
trol group). E: Total nitrite+nitrate content in A549 cell cul-
ture medium after 48 hours exposure to either cytomix or 
IL-13 was measured (n = 8, *P < 0.05 compared to control 
group).Respiratory Research 2009, 10:3 http://respiratory-research.com/content/10/1/3
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induces a modest NO release from SAECs between 30 to
48 hours with a peak of 0.06 ± 0.03 pl.s-1.cm-2, and does
not induce NO release from A549 cells (Fig. 2B, D). No
significant relation was found between gas phase NO level
and days of air-liquid interface (range 7–21 days). No sig-
nificant variability in NO production was observed
among the three SAEC donors.
Total nitrite+nitrate content in the culture medium is
another index of total NO production. In SAECs and A549
cells, the total nitrite+nitrate content in the culture
medium of the cytomix treated group was significantly
higher from control and IL-13 treated cells (Fig. 2C, E)
while the total nitrite+nitrate content of in the culture
medium of the IL-13 treated group was not significantly
different from control cells (Fig. 2C, E). Addition of iNOS
inhibitor at 24 hours to cytomix treated SAECs resulted in
less total nitrite+nitrate content in the medium than the
uninhibited group (Fig. 2C).
NOS gene and protein expression in SAECs and A549
Unstimulated SAECs and A549 cells did not express
detectable iNOS protein by Western blot, but cytomix
induced iNOS protein expression in a pattern consistent
with NO gas phase release both temporally and in magni-
tude (Fig. 3A, C and 3D). IL-13 steadily induced iNOS
protein expression from 10 hours to 48 hours in SAECs
(Fig. 3B), and did not alter iNOS protein expression in
A549 (Fig. 3E). iNOS, eNOS and nNOS RT-PCR were per-
formed to investigate the expression of NOS isoforms. A
very low level of iNOS mRNA was detected in the control
group of SAECs. At t = 48 hours, both cytomix and IL-13
demonstrated elevated iNOS mRNA expression (Fig. 3F).
nNOS mRNA was expressed in the control group, but was
not upregulated by cytomix or IL-13 simulation (Fig, 3G).
eNOS mRNA was not present in SAECs under any condi-
tions (Fig. 3H).
Discussion
Small airway (airway diameter < 1–2 mm) inflammation
is thought to play a critical role in the pathogenesis of
asthma including airways hyper-responsiveness, sponta-
neous exacerbations of symptoms, and tissue remodeling
[3]. Non-invasive markers of inflammation, such as NO
gas in the exhaled breath, could assist in the management
of airway inflammation, but the anatomical source
remains unclear. Our study demonstrates that small air-
way epithelial cells can be differentiated at an air-liquid
interface to express markers such as mucin and cilia. The
differentiated epithelium produces a very small, but
detectable, amount of NO gas at baseline. However, the
production is significantly increased, due to the upregula-
tion of iNOS, following exposure to soluble inflammatory
mediators, most notably a combination of IL-1β, TNF-α
and IFN-γ. As such, iNOS in the small airway epithelium
is a probable source of NO in the exhaled breath of
asthma.
Bronchioles are generally < 1 mm in diameter, are devoid
of cartilage, and are lined with cuboidal epithelial cells.
Ciliated cells and mucous producing goblet cells are
present, but are less abundant than in larger airways [15].
SAECs are sourced from 1 mm diameter airways (approx-
imately generation 10–12) of normal human subjects, in
contrast to normal human bronchial epithelial cells
(NHBEs, Lonza) which arise from the trachea (generation
0). Our results demonstrate that SAECs can be cultured at
an air-liquid interface for seven days and express mature
differentiated markers such as β-tubulin and MUC5AC,
markers of cilia and goblet cells. In addition, the cells
form a confluent monolayer with a transepithelial electri-
cal resistance (TER) that is similar in magnitude to the
NOS gene and protein expression in cytomix or IL-13 stimu- lated SAECs and A549 cells Figure 3
NOS gene and protein expression in cytomix or IL-13 
stimulated SAECs and A549 cells. A: Cytomix upregu-
lated iNOS protein expression in a pattern consistent with 
NO flux in SAECs. B: IL-13 steadily enhanced iNOS protein 
expression from 10 hours to 48 hours in SAECs. C: Densit-
ometry analysis of iNOS protein expression in SAECs nor-
malized by β-actin (n = 3). D: Cytomix induced iNOS protein 
expressions in A549 cells within 6 hours, reaching a peak at 
10 hours. E: IL-13 did not enhance iNOS protein expression 
within 48 hours in A549 cells. F: Cytomix and IL-13 enhance 
iNOS mRNA expression after 48 hours exposure in SAECs. 
G: nNOS mRNA was expressed at baseline in SAEC, but was 
not altered by cytomix or IL-13 simulation. H: eNOS mRNA 
was not present in SAECs under basal or cytokine-stimulated 
conditions.Respiratory Research 2009, 10:3 http://respiratory-research.com/content/10/1/3
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NHBEs. The markers of differentiation were detectable as
early as 5 days of air-liquid interface, and no significant
difference was observed between 7 days and 14 days dif-
ferentiation (data not shown).
The airway epithelium has been proposed as a major
source of NO in the exhaled breath, and our previous
work demonstrated that epithelial cells of tracheal origin
can produce NO gas at levels which are consistent with
that observed in the exhaled breath of healthy subjects.
However, asthma is thought to be an inflammatory dis-
ease of the smaller airways. The phenotypic features of the
airway epithelium change with increasing airway genera-
tion. For example, as airway generation increases (smaller
diameter airways), the epithelium becomes less columnar
(flatter) in shape, expresses less cilia, and produces less
mucus [15]. These changes reflect the transition from a
barrier function to trap and remove particulates in the
inspired air to the gas exchange function of the alveolar
region. Our previous results demonstrated significant NO
production and release from NHBE at baseline and in
response to IL-13 [8]; hence, our results suggest that NO
metabolism may also be different in large and small air-
way epithelium.
At baseline, SAECs released 0.005 ± 0.002 pl.s-1.cm-2(Fig-
ure 2B) into the gas phase which is approximately an
order of magnitude less than the basal NO release from
NHBEs (0.05 ± 0.03 pl.s-1.cm-2) [8]. However, if the
increase in surface area with increasing generation
number is considered (surface area of adult trachea is ~70
cm2, and that of generation 10 is approximately 300 cm2),
the contribution from these regions to exhaled NO would
be of the same order of magnitude (3.5 pl.s-1 for the tra-
chea and 1.5 pl.s-1 for generation 10). This is consistent
with previous reports demonstrating that the main bron-
chus and trachea contribute approximately 50% of the
exhaled NO in normal subjects [16]. Similar to NHBEs [8]
and other primary epithelial cells [14], unstimulated
SAECs express mRNA for nNOS (NOSI); hence, baseline
production is likely due to constitutive expression of
nNOS as iNOS protein and eNOS (NOS III) mRNA were
not detectable.
Several previous studies have demonstrated that cytomix
can induce iNOS expression and nitrite release in A549
cells [9,10], and a combination of TNF-α and IFN-γ
increases nitrite content in the medium of NHBEs [17].
Cytomix has also been reported to markedly stimulate
iNOS expression in other cells such as intestinal cells [18]
and hepatocytes [19]. Our results demonstrated a similar
effect of cytomix on iNOS expression and NO release in
SAECs and A549 cells. Stimulated by cytomix, SAECs and
A549 cells increase gas phase NO release rapidly reaching
a peak by 10 hours. The increase correlates temporally
with an increase in iNOS protein, and is matched by an
increase in total nitrite+nitrate in the media 48 hours after
stimulation. The peak NO release from A549 cells and
SAECs is similar, but the production is more sustained in
SAECs. By 48 hours, the NO release from A549 is back to
baseline. The smaller total NO production over the 48
hour time window for A549 cells is reflected in less total
nitrite+nitrate (15.5 μM compared to 45 μM). The obser-
vation that iNOS protein levels peak at the same time as
NO gas release, combined with the elimination of NO
release following iNOS inhibition, suggests a direction
relationship between iNOS protein level and NO release.
Our previous study in NHBEs demonstrated that 10 ng/
ml IL-13 leads to a significant increase in NO flux at 10
hours, and a maximum flux (7.4 pl.s-1.cm-2) at 24 hours
[8]. Another recent study also demonstrated that IL-13 can
increase iNOS mRNA expression as early as 5 hours after
stimulation in primary human airway epithelial cells [14]
obtained from bronchial brushings of larger airways. We
found that 10 ng/ml IL-13 only modestly and slowly
increases NO release from SAECs reaching a peak (0.06
pl.s-1.cm-2) around 30 to 48 hours, which is approximately
an order of magnitude smaller and 24 hours slower com-
pared to NHBEs. Our results confirm the ability of IL-13
to enhance NO release and iNOS expression in airway epi-
thelium, and show a pattern in small airway epithelial
cells that is distinct from A549 cells. Consistent with pre-
vious studies, IL-13 does not impact nitrite production
[20] or NO gas release from A549 cells.
The distinct pattern of SAECs in response to cytomix and
IL-13 and the difference between SAECs, A549 cells, and
NHBEs in response to inflammatory cytokines may assist
in the interpretation of the exhaled NO signal. The inflam-
matory response of asthma is critical to disease progres-
sion and therapy. One theory of asthmatic inflammation
describes an imbalance in the Th1 and Th2 lymphocyte
and cytokine profile. The former produce primarily IL-2
and IFN-γ, and are generally responsible for mounting an
immune response to infection. The later produce IL-4, IL-
5, IL-6, IL-9, and IL-13 and primarily account for mount-
ing the allergic response. In some asthmatic phenotypes,
there may be an imbalance favoring the Th2 response.
This is supported by numerous studies showing elevated
Th2-type cytokines in the peripheral blood, bronchial
biopsies, and bronchoalveolar lavage [21-24]. In contrast,
there is significant evidence supporting Th1-type inflam-
mation in asthma from the increased levels of IFN-γ in the
blood and induced sputum [25]. The latter may be a
response that modulates the Th2 type inflammation
through an epithelial-derived nitric oxide mediated path-
way [26]. Furthermore, additional inflammatory
cytokines such as IL-1β and TNF-α are derived primarily
from macrophages (not Th1 or Th2-derived) and also playRespiratory Research 2009, 10:3 http://respiratory-research.com/content/10/1/3
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a significant role in asthma inflammation. Asthma is
clearly a heterogeneous disease in onset, severity and
response to therapy, and this observation may be, in part,
due to the heterogeneous nature of the inflammation.
While stimulation with cytomix and IL-13 are not meant
to recapitulate Th1 and Th2 inflammatory responses, they
do represent different features of inflammation.
An important feature of exhaled NO is the significant var-
iability reported within a group of clinically similar indi-
viduals (e.g., healthy controls, asthma, cystic fibrosis,
etc.). As with most biological signals, exhaled NO demon-
strates a log normal distribution. At a constant exhalation
flow of 50 ml/s (American Thoracic Society guidelines),
the geometric mean value in healthy children (age 4–17
years) is 9.7 ppb, but the upper end of the 95% confidence
interval is 25.2 ppb [27]. Similarly large ranges in healthy
adults and clinically similar groups of subjects with
asthma are invariably reported. These findings strongly
suggest that our knowledge of the underlying source and
determinants of exhaled NO remain crude. Our results of
NO gas phase release from epithelial cells suggests the pre-
dominant type of inflammation and the anatomical
source of the inflammation may be contributing factors to
the variability of NO in the exhaled breath. For example,
elevated Th2-type cytokine (IL-13) in large airways may
lead to a significant increase in exhaled NO level; how-
ever, the same cytokine in the smaller airways may have
little effect on exhaled NO.
Our in vitro system consisting of the airway epithelium for
direct NO gas phase measurement enhances our under-
standing of the cellular-based mechanisms that affect
exhaled NO. Our results demonstrate that NO gas phase
release from SAECs and A549 is minimal at baseline, but
is increased by cytomix reaching a rapid peak 10 hours fol-
lowing stimulation. In contrast, IL-13 does not impact
NO gas phase release in A549, but does increase NO pro-
duction in SAECs much more slowly. The NO release is
closely linked temporally and in magnitude with iNOS
protein levels.
Conclusion
Together with previous results from NHBEs, we conclude
that the lung epithelium can produce and release NO into
the gas phase, and is the likely source of NO in the exhaled
breath. However, the dynamics and magnitude depend
strongly on the inflammatory stimulus and the anatomi-
cal location, which may contribute to the intersubject var-
iability of the exhaled NO signal.
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